Price T Rowe Associates Inc. MD Sells 6,369,269 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Price T Rowe Associates Inc. MD trimmed its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 99.0% during the fourth quarter, Holdings Channel reports. The firm owned 64,777 shares of the company’s stock after selling 6,369,269 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Gossamer Bio were worth $59,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Silverarc Capital Management LLC raised its holdings in shares of Gossamer Bio by 9.3% in the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after purchasing an additional 526,495 shares during the period. Smith Moore & CO. raised its holdings in shares of Gossamer Bio by 32.7% in the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company’s stock valued at $271,000 after purchasing an additional 74,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock valued at $2,037,000 after purchasing an additional 38,084 shares during the period. Monaco Asset Management SAM grew its stake in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after buying an additional 1,520,721 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after buying an additional 13,902 shares during the last quarter. 81.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GOSS. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Friday. Finally, The Goldman Sachs Group upped their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday.

Gossamer Bio Stock Down 1.0%

Shares of GOSS opened at $1.04 on Monday. The firm’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $0.99. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.55. The firm has a market cap of $236.31 million, a P/E ratio of -3.25 and a beta of 1.82. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. On average, analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.